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ABSTRACT
Objective To determine whether and how eligibility
criteria of participants prespecified in protocols of
randomised trials are reported in subsequent articles.
Design Cohort study.
Setting Protocols submitted to the ethics committee of a
German medical faculty.
Data sources 52 trial protocols and 78 subsequent
publications published between 2000 and 2006.
Main outcome measure Proportion of matching, missing,
modified, or newly added eligibility criteria between trial
protocols and subsequent publications.
Results Differences were found between protocols and
subsequent publications for all 52 trials. Information on
eligibility criteria was missing in the publications for all 52
trials (100%, 95% confidence interval 93% to 100%),
modified for 44 (85%, 72% to 93%), and newly added for
21 (41%, 27% to 55%). The mean number of eligibility
criteria for each trial was 25 (range 7-43) and the mean
proportion of matching eligibility criteria per trial was 50%
(95% confidence interval 44% to 55%, range 13-93). Of
1248 eligibility criteria prespecified in the protocols, 606
(49%, 46% to 51%) were matching in subsequent
publications, 479 (38%, 36% to 41%) were missing, and
163 (13%, 11% to 15%) were modified. 51 eligibility
criteria were added to publications. Most prespecified
eligibility criteria were about comorbidity (42%, 39% to
45%), treatment (20%, 18% to 22%), or type or severity of
illness (17%, 15% to 19%). Most of the missing eligibility
criteria (96%, 94% to 97%) and modified eligibility criteria
(54%, 46% to 62%) suggested broader study populations
and most of the added eligibility criteria (86%, 74% to
94%) suggested narrower study populations.
Conclusions Many users of trial information rely on
published journal articles. These articles generally do not
reflect the exact definition of the study population as
prespecified in the protocol. Incomplete or inadequate
reporting of eligibility criteria hampers a proper
assessment of the applicability of trial results.
INTRODUCTION
Published information about clinical trials is often
incomplete.
1 If the reporting is selective the available
information misrepresents the scientific evidence. It
has long been recognised that only part of the results of
trials are published in peer reviewed journals. For
instance, “positive” results confirming the effect of new
treatments are more likely to be published.
2 Evidence is
now accumulating that not only entire studies but also
individualstudyoutcomesarereportedselectively,lead-
ing to outcome reporting bias.
34 The reporting of trial
results and related biases has been studied extensively,
but less is known about how the design of trials and
methods is reported. Definitions of medical inter-
ventions have been shown to be reported
incompletely.
5Incompletereportingoftrialsalsooccurs
forotherkeyinformation,suchasthecalculationofsam-
ple size and methods of statistical analysis. For example,
only 18% of trials approved by a scientific ethics com-
mittee in Denmark in 1994-5 described a priori sample
sizecalculationsadequatelyinboththeprotocolandthe
publications.
6 Differences between protocols and publi-
cations were also found for the reporting of allocation
concealment and adverse events.
78
Little is known about the reporting of the eligibility
criteriausedforselectionoftrialparticipants.Aprecise
definition of a trial’s study population is important to
assess whether results can be applied to other patients
with the same condition.
9 Trial participants often do
not represent the patient population that clinicians
see in their daily practice.
10-12 If, for example, it is
unclear whetherpatientswithparticular comorbidities
were excluded from a trial, practitioners using the trial
report for medical decision making cannot know
whether the results can apply to their patients with
one of these comorbidities. Unreported exclusion cri-
teria falsely let the reader assume that the results of a
trialaremorewidelyapplicable.Apatientwithseveral
health problems may, however, be at increased risk of
severe side effects of the intervention.
We characterised the eligibility criteria defined in
trialprotocolstoinvestigatewhethertheyare reported
in subsequent articles and described trial characteris-
tics potentially associated with differences in the
reporting of eligibility criteria.
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Cohort of study protocols
The research ethics committee of the University of
Freiburg, Germany, granted access to all study proto-
cols submitted in 2000 for approval,including amend-
ments, progress reports, and correspondence. We
classified the design of all submitted studies and
included only randomised controlled trials. Of 141
randomisedcontrolledtrialsidentified,103were com-
pleted.Thefactorialdesignwasconsideredavariantof
aparallelgroupdesign;weclassifiedcrossovertrialsas
randomisedstudiesonlyifthetreatmentallocationhad
been randomised. We systematically searched Med-
line (Ovid), the Cochrane Central Register of Con-
trolled Trials, Current Contents, full-text databases of
several publishers, and the university’s publication
registry up to March 2007. For each protocol we
designeda newsearchstrategyincludingrelevant key-
words,suchasexperimentaldrug,studynameoracro-
nym, studied disease or condition, and names of
applicants,whichalsoallowedforvariantsofkeywords
and additional search terms. The literature search was
complemented by a survey of the investigators asking
them to confirm corresponding publications already
identified by us and to indicate additional ones. The
methodology is described in detail elsewhere.
13
Data collection
We screened the trial protocols and amendments for
information on eligibility criteria. Relevant informa-
tion that waslabelleddifferentlyor foundin other pro-
tocol sections or in a synopsis was also considered
pertinent.Astheprotocolwasunavailablefortwotrials
weusedtheinformationonthemandatoryapplication
form submitted to the ethics committee, which
required information on eligibility criteria. Data were
extracted into a spreadsheet and compared with those
reported in the publications. We classified eligibility
criteriaintosevencategoriesaccordingtotheircontent
(box). The classification was developed as we went
along with data extraction, and reassessed for consis-
tency after completion.
We then classified eligibility criteria as matching,
missing from, modified, or added in a publication.
Eligibility criteria were considered matching if infor-
mation specified in the protocol was identical in the
publications, missing if not reported in the publica-
tions, and modified if reported in the publications but
changed in minor aspects. Eligibility criteria not pre-
specified in the protocol but newly mentioned in pub-
lications were classified as added. When comparing
information in protocols with that in publications we
focusedonthecontentratherthanexactwording.Ifan
eligibilitycriterionwasdescribedasaninclusioncriter-
ioninonesourcebutanexclusioncriterionintheother
we regarded it as matching. Criteria mentioned twice
in the same data source (for example, termed as inclu-
sion and exclusion criterion) were considered only
once. If eligibility criteria were changed in amend-
ments to the protocol, we considered the most recent
information.Forprotocolswithseveralcorresponding
articlesweregardedaneligibilitycriterionasmatching
if the information in the protocol matched with at least
onearticleandasmissingifnotmentionedinanyofthe
articles. If publications referredto studymethods pub-
lished elsewhere, we retrieved this additional informa-
tion. From the publications we extracted the
definitions of the study population only as stated in
the methods sections and disregarded information
about the study population actually achieved (such as
the baseline characteristics of participants usually
described in the results section). If an eligibility criter-
ionwascomposedoftwoormorecriteriawe classified
each separately. For example, in one trial, participants
with a history of major surgery or trauma within the
past three months were excluded, and we regarded
this as two criteria, one related to treatment (surgery)
and one to comorbidity (trauma). Two investigators
independently extracted all data; a total of four inves-
tigators participated in data extraction. Disagreements
were resolved by discussion and consensus.
For each missing, modified, or added criterion, we
considered whether the difference between protocol
and publication would broaden or narrow the study
population assumed by a reader of the publication.
For example, if the age range of participants was
defined as “60-80 years” in the protocol but not in the
publication, readers would assume that people aged
under 60 and over 80 were also eligible and would
infer a broader study population. Inversely, readers
would assume a narrower study population if comor-
biditieswerementionedasexclusioncriteriainthetrial
report but not in the protocol.
Statistical analysis
Our study is based on a sample of trial protocols, each
including several eligibility criteria. We analysed the
Categories of eligibility criteria according to content
Comorbidity
Previous or current health condition not studied in the trial. Also used if investigators were
allowed to exclude people for any other health condition
Treatment
Previous or current drug intake, surgery, or participation in another study
Type or severity of illness
Illness or health condition studied in the trial
Pregnancy related criteria
Criteria concerning pregnancy, lactation, and contraceptive methods
Personal criteria
Examples are age, sex, ethnicity
Diagnostic procedure
Concerns the procedure, not the result, of a diagnostic measurement. Examples are
measurement of blood pressure or a specific laboratory test as a prerequisite for
participation in the trial
Other
Examples are specific individual criteria, such as exclusion if a partner is pregnant or
inclusion depending on place of residence, or informed consent. Also used if investigators
were allowed to exclude people for any other reason, such as anticipated non-compliance
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unitofanalysiswitheligibilitycriteriastratifiedbytrial
(analyses based on trial protocols). For each trial we
calculated separately the proportion of eligibility cri-
teria matching between protocols and publications
(nominator) and all eligibility criteria defined in the
protocol(denominator).Forproportionswecalculated
binomial 95% confidence intervals. The primary out-
come was the proportion of matching eligibility cri-
teria. Using an exploratory approach, we investigated
whether the proportion of matching eligibility criteria
was associated with key characteristics of the trials,
including sample size, centre status (multicentre or sin-
gle centre study), and industry funding or other. For
instance, we wondered whether the interests or con-
straints of authors carrying out large multicentre trials
funded by industry would differ from those of authors
carrying out small investigator driven trials and
whether this would result in discrepancies in the study
populations defined in the protocols and subsequent
trial reports. We used a multiple linear regression
model to assess the relations between the logit trans-
formed proportion of matching eligibility criteria and
study characteristics. Secondly, we used the individual
eligibility criterion as the unit of analysis (analyses
basedoneligibilitycriteria)tocalculatethedistribution
of inclusion or exclusion criteria for each content cate-
gory and the different types of eligibility criteria
(matching, missing, modified, added). We used Stata/
SE 10.1 for Unix (February 2009) for calculations.
RESULTS
One or more publications were identified for 54 of the
103 completed trials (52%, 95% confidence interval
42% to 62%). One protocol was excluded because it
was on diagnostic devices and another because subse-
quent publications referred to a cross sectional sub-
study. The final sample comprised 52 trial protocols.
In 30 of these (58%, 43% to 71%) study methods were
changed, as documented in the amendments sub-
mitted to the research ethics committee. In 13 (25%,
14% to 39%) protocols the eligibility criteria were
changed. Table 1 lists the characteristics of the trials.
Overall, 78 trial reportspublished between 2000 and
2006 were identified in 50 journals: 36 trials resulted in
onepublicationeachand16intwoormore.Onearticle
referredtoanonlinedatasupplementandtwoothersto
documents specifying eligibility criteria, but none
included further definitions of the study population.
Analyses based on trial protocols
In all52 trials differenceswere found betweenthe pro-
tocol and subsequent publications. Eligibility criteria
were missing in the publications for all 52 trials
(100%, 93% to 100%), modified for 44 (85%, 72% to
93%),ornewlyaddedfor21(41%,27%to55%).Across
all 52 trials the proportion of matching eligibility cri-
teria ranged between 13% and 93% (mean 50%, 95%
confidence interval 44% to 55%).
Variables included in the exploratory regression
model were sample size, centre status, and industry
and other funding. These study characteristics were
notassociatedwiththeproportionofmatchingeligibil-
itycriteria,althoughthestatisticalpowertodetectasso-
ciations may have been low (table 2).
For each of the 52 trials the proportion of missing or
modified criteria that would lead a reader to assume a
broader or narrower study population was calculated.
Table 1 |Characteristics of included trials
Characteristics No (%) of trials (n=52)
Medical domain:
Haematology or oncology 11 (21)
Cardiology or angiology 4 (8)
Dermatology 4 (8)
Pneumology 3 (6)
Gynaecology 3 (6)
Radiology 3 (6)
Urology 2 (4)
Endocrinology 2 (4)
Nephrology 2 (4)
Clinical chemistry 2 (4)
Anaesthesiology 2 (4)
Forensic medicine 2 (4)
Ophthalmology 2 (4)
Psychiatry or psychosomatic medicine 2 (4)
Gastroenterology 1 (2)
Rehabilitation 1 (2)
Rheumatology or immunology 1 (2)
Other 5 (10)
Centre status:
Single centre 7 (13)
Multicentre 45 (87)
International 32 (62)
National 9 (17)
Unclear 4 (8)
Leading study centre:
Freiburg 5 (10)
Other 40 (77)
Unclear 7 (13)
Industry funding:
Yes 36 (69)
No 16 (31)
Other funding
Yes 6 (12)
No 46 (88)
Sponsor involved in planning and conduct
of trial:
Yes 32 (62)
No 20 (38)
Study design:
Parallel group 47 (90)
Crossover 5 (10)
No of study groups:
2 39 (75)
>2 13 (25)
Sample size:
Range 10-8300
Median 220
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because the direction of influence was unclear. The
mean proportion of criteria suggesting a broader
study population was 85% (95% confidence interval
80% to 91%, range 20-100). The mean proportion of
criteriasuggestinganarrowerstudypopulationwas9%
(5% to 13%, range 0-50).
Analyses based on eligibility criteria
Overall, 1248 eligibility criteria were identified in the
52protocols;ofthose,606(49%,95%confidenceinter-
val46%to51%)werematchinginthepublications,479
(38%,36%to41%)weremissing,and163(13%,11%to
15%) were modified. Fifty one eligibility criteria relat-
ingto21trialswerenotmentionedintheprotocolsbut
were added to the publications. Table 3 gives exam-
plesofthesediscrepancies.Trialprotocolscompriseda
mean of 25 eligibility criteria (range 7-43). Of all 820
eligibilitycriteriareportedinthepublications,6%were
added. Most of the missing eligibility criteria (96%,
94% to 97%) and modified eligibility criteria (54%,
46% to 62%) suggested broader study populations,
and most of the added eligibility criteria (86%, 74% to
94%) suggested narrower study populations. Of all
1299 eligibility criteria mentioned in either protocols
or publications or both, 422 (32%, 30% to 35%) were
inclusion criteria and 856 (66%, 63% to 69%) were
exclusion criteria. In one trial, 21 eligibility criteria
(2%,1%to3%)werelabelledneutrallyaspatientselec-
tion criteria. A mean of eight criteria were related to
inclusion and 16 to exclusion.The most common con-
tent category was comorbidity, followed by treatment
andtypeorseverityofillness(table 4).Criteriarelated
tocomorbidity,treatment,andpregnancyweremainly
expressed as exclusion criteria, whereas criteria on
type or severity of illness, personal characteristics,
and diagnostic procedures were mostly inclusion cri-
teria.Thesevencontentcategorieshadsimilarpropor-
tions of matching and not matching criteria (figure).
DISCUSSION
Considerable differences exist between the eligibility
criteria specified in protocols of randomised trials and
what is reported in subsequent publications. For all
trials a proportion of prespecified eligibility criteria
were either missing or modified in the publications.
To a much lesser extent, eligibility criteria were not
prespecified in the protocols but were added to the
publications. Our findings are supported by an earlier
analysis of reports of trials in hip and knee osteoarthri-
tis showing that key information needed to assess the
external validity of trials was poorly reported.
14 In fact
essential information such as the method and duration
of recruitment was described in less than half of the
examined publications. Furthermore, in an analysis
of 283 reports of trials published between 1994 and
2006 in high profile general medical journals the
reporting of exclusion criteria was often poor and
incomplete.
15 In this analysis, 84% of trial reports con-
tained at least one poorly justified exclusion criterion,
and in 61% more than one quarter of the trial’s exclu-
sion criteria were poorly justified. Our study did not
allow for the effect of the discrepancies on study size
or results to be quantified. This would have required
access to the individual data of all people eligible for
and participating in the 52 trials. Our findings suggest
that discrepancies in the reporting of eligibility criteria
are common. This has several implications. Firstly,
most discrepancies would let readers assume a falsely
broader study population, consequently inferring
wider applicability of the trial’s results. For example,
in one trial, participants with “primary refractory dis-
ease” were excluded according to the protocol but
included according to the publication (table 3). Clin-
icians using the trial results in practice could assume
thatthestudyinterventionhadbeenstudiedinpatients
with primary refractory disease and might consider
treating such patients accordingly. Secondly, differ-
ences in study populations are a source of heterogene-
ity in the synthesis of trial results, such as in meta-
analyses.
16 A proper analysis of sources of study het-
erogeneity is hampered if researchers are unable to
determine a difference between study populations in
trials investigating the same or similar interventions.
Thirdly, the published information often did not
allow determination of the exact study population but
was suggestive of broader study populations in most
Table 2 |Results of multiple regression analysis of factors
potentially associated with proportion of matching eligibility
criteria
Variable
Odds ratio
(95% CI) P value
Intercept 0.63 (0.24 to 0.91)
Sample size* 1.01 (0.80 to 1.27) 0.93
Multicentre v single centre trial† 0.58 (0.24 to 1.40) 0.22
Industry funding v none† 1.32 (0.65 to 2.71) 0.44
Other funding v none† 1.94 (0.73 to 5.14) 0.18
*Interpreted as relative increase in proportion of matching eligibility
criteria per each one unit increase in log transformed sample size.
†Interpreted as relative increase or decrease in proportion of matching
eligibility criteria compared with reference category.
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inawiderapplicabilityoftheirresults—forexample,in
different age groups or subgroups of patients with
other types or stages of disease.
17 Consequently, any
ambiguous information may influence policy deci-
sions, such as the patient groups for which a new drug
will be approved.
On average, the trial protocols in our study had 16
exclusion criteria, and many of these were about
comorbidity or concomitant medical treatments, thus
confirming results of an earlier study.
15 Consequently,
individualseligiblefortrialinclusionaremoreselected
and homogenous than the populations of patients in
which study results will be applied later. In most of
the studied trials clinical criteria such as comorbidity
wereusedtodecideoneligibility.Accordingly,anear-
lier analysis of randomised controlled trials on HIV
showed that by using such criteria a large part of a
representative cohort of women infected with HIV in
theUnitedStateswouldhavebeenexcluded frompar-
ticipation in the trial.
18
Selectiveenrolmentofparticipantswasalsofoundin
cardiovascular trials. Relative to their disease preva-
lence women and adults aged 75 or older were under-
represented in trials of acute coronary syndromes,
although formal eligibility criteria did not preclude
their participation.
19 It has been recommended that
each eligibility criterion should be justified explicitly
and reassessed when new trials are planned.
20 Almost
all study protocols used the distinction between inclu-
sion and exclusion criteria. Only one used the term
“patientselectioncriteria”.Ithasbeenarguedthatelig-
ibility criteria can be formulated in both ways and that
listing the same conditionas an inclusion criterion and
again as an exclusion criterion in the protocol is
redundant.
15
Limitations and strengths of the study
We accessed trial protocols approved during one year
by theresearchethicscommittee ofa Germanmedical
facultyandusedrigorousandcomprehensivemethods
toascertainsubsequentfullpublications.Nevertheless,
we identified publications for only about half of the
included trials.
13 This low proportion of fully pub-
lished trials is consistent with findings from other
cohorts following trials from the protocol stage to full
publication.
2Giventhatethicalapprovalismandatory
and inclusion of protocols in our study did not depend
onthetrialists’consent,theincludedtrialsrepresented
an unbiased sample of interventional clinical research
projects. As most trials were international multicentre
studies our findings may well be applicable to trial
reports from other settings or countries. However,
our data sources also have some limitations. We
could not ascertain whether the accessed files com-
prised all the documents of the submitted trials. For
two trials the detailed study protocol was not available
(multicentre studies already approved elsewhere), and
data extractions were solely based on the study infor-
mation requested in the mandatory application forms.
The study protocols were written about 10 years ago
and the corresponding publications in the following
years. If the reporting of eligibility criteria has
improved in the meantime our findings would prob-
ably overestimate the current magnitude of the pro-
blem. Some of our study methods were developed for
the purpose of this study. For example, in the absence
of a standard we developed our own classification for
content categories. We used some common sense
approaches, such as defining what represents a differ-
ence or not, and in these instances alternatives would
have beenconceivable.Furthermore,the sampleof52
trialsmighthavebeentoosmalltoidentifyfactorsasso-
ciated with a higher proportion of discrepancy in elig-
ibility criteria.
Possible reasons for discrepancies
Trial protocols often comprise detailed descriptions of
studymethodslargelyexceedingthelengthofmethods
sections in journal articles. Restrictions on print space
have been a possible reasonfor discrepancies between
protocols and subsequent publications in the past and
may have explained why eligibility criteria deemed
lessimportantwereomittedfromjournalmanuscripts.
Withtheriseinelectronicpublishing,journalsincreas-
ingly offer publication of comprehensive versions of
Table 3 |Examples of eligibility criteria that differed between trial protocols and subsequent publications
Protocol including amendments Publication Impact on readers’ interpretation
Type or severity of illness:
Hormone plasma level <280 ng/dl (exclusion criterion) Hormone plasma level <240 ng/dl (exclusion criterion) Broader study population
Crohn’s disease activity index 220-400. In amendment:
180-400 (inclusion criterion)
Crohn’s disease activity index >220 (inclusion criterion) Unclear because of ambiguity between amendment to
protocol and publication
Personal criteria:
Age range 30-80 years (inclusion criterion)* Age range 18-80 years (inclusion criterion); age >50 and
<20 years (exclusion criterion)
Unclearbecauseofambiguitybetweenreportedinclusionand
exclusion criterion
Comorbidity:
Primary refractory disease (exclusion criterion) Primary refractory disease (inclusion criterion) Broader study population
Diabetes mellitus (exclusion criterion) Other endocrine or metabolic diseases (exclusion criterion) Narrower study population
Other criteria:
Not stated Common exclusion criteria of clinical studies Narrower study population
*Stated only on application form, not in protocol.
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restrictions should no longer be a reason for omission
ofimportantinformationfrompublications.Wefound
many modified or additional criteria in the publica-
tions. Clearly, changes to eligibility criteria may
become necessary, for instance because of problems
during the study course such as slow recruitment of
trial participants or unexpected side effects in a parti-
cular group of participants. However, in these cases,
the changes to the study protocol should be documen-
ted in amendments of the original study protocol.
Furthermore, prespecified criteria, such as the exclu-
sion of people with relatively rare comorbidities, pos-
sibly were never applied during recruitment of
participants and consequently not mentioned in later
publications. Lastly, the observed inaccuracy in
reporting of trial information may have other reasons
suchasdifferentauthorsofprotocolsandpublications,
long time lags between the writing of protocols
and publications, or mere carelessness in drafting
manuscripts.
With our approach, a protocol listing detailed elig-
ibility criteria probably yields more discrepancies in
subsequentpublicationsonthelevelofindividualelig-
ibility criteria than a protocol with only broad terms,
such as for target diseases or comorbidities. Impor-
tantly, our study could not determine any causes of
discordance and to what extent the observed differ-
ences reflected real changes during study conduct.
What could be done?
The consolidated standards of reporting trials (CON-
SORT) statement aims at helping authors include all
the essential information in reports about medical
research.
21Acompletedescriptionofeligibilitycriteria
is one of its elements. Although the CONSORT state-
mentwasfirstpublishedin1996,the reportingoftrials
is still poor at present.
2223 If in trial reports some elig-
ibility criteria are reported as prespecified but others
are modified or not reported at all, it is impossible for
readers to obtain a clear view on who actually was eli-
gible to participate in a given trial. Of the 50 journals
publishing the 78 articles included in our study, 23
(46%) endorsed the CONSORT statement in their
author instructions (as of May 2009). However, an
assessment of the completeness and correctness of the
information on study populations in submitted manu-
scriptswouldrequireaccesstothetrialprotocols.Con-
sequently, some journals ask for the protocol to be
submitted along with the manuscript. To improve the
content of protocols of randomised controlled trials,
the standard protocol items for randomized trials
(SPIRIT) initiative is currently developing guidelines
for the core information to be included in trial
protocols.
24
Carefully drafted protocols may also lead to
improvedinformationinpubliclyaccessibletrialregis-
tries. These registries are a valuable source of study
information, allowing users to retrace and compare
the definitions used at the different stages of the
research.
4 Twenty items are considered the minimal
set of trial information that the World Health Organi-
zation’s international clinical trials registry platform
requests for a trial to be regarded as prospectively
registered, of which one is about inclusion and exclu-
sioncriteriaforparticipantselection.
25Mandatorypro-
spectivetrialregistrationhasbecomearequirementfor
publication of trial reports in many journals.
26 Better
access to the detailed study information would facili-
tate the assessment of the validity of clinical trials.
27
Consequently,trialprotocolsshouldbemadepublicly
accessibletomaketheconductandreportingofclinical
research more transparent.
Conclusion
Weshowedthattheeligibilitycriteriapublishedintrial
reports do not adequately reflect those prespecified in
the study protocols. This may have consequences for
clinical practice, research, and policy. Even if a reader
has precise information about a trial’s study popula-
tion, the interpretation of published results of thera-
peutic research is fraught with problems. In contrast
with a study’s internal validity, its applicability cannot
be assessed without substantial information that goes
beyondthestudyitself.
28Oftenitisunclearwhetheran
experimentalinterventionisalsoeffectiveinadifferent
clinical scenario.
92930 The difficulties in using trial
results in clinical practice, research, and policy aug-
mentifthepublishedinformationonthestudypopula-
tions is incomplete or reported selectively.
Table 4 |Eligibility criteria classified by content category and type of discrepancy of protocol and subsequent publications
Content category No of trials
Total No (%) of eligibility
criteria
No (%) of eligibility criteria
Matching
Missing in
publication
Modified in
publication
Added in
publication
Comorbidity 52 546 (42) 212 (39) 227 (41) 80 (15) 27 (5)
Treatment 49 258 (20) 107 (41) 105 (41) 34 (13) 12 (5)
Type or severity of illness 51 223 (17) 139 (62) 46 (21) 34 (15) 4 (2)
Pregnancy related criteria 43 73 (6) 35 (48) 34 (46) 2 (3) 2 (3)
Personal criteria 51 67 (5) 44 (66) 17 (25) 5 (7) 1 (2)
Diagnostic procedures 13 30 (2) 12 (40) 15 (50) 3 (10) 0
Other 47 102 (8) 57 (56) 35 (34) 5 (5) 5 (5)
Total 1299 (100) 606 (46) 479 (37) 163 (13) 51 (4)
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Deficiencies in the reporting of results from randomised trials have been described
Trial reports often lack important information about study methods, such as randomisation
Detailedinformation ontrial participants is important for readers who want toknowtowhom
the results can be applied
WHAT THIS STUDY ADDS
Published eligibility criteria did not adequately reflect the study populations as prespecified
in trial protocols; about half of the eligibility criteria were either modified or not reported in
the publications
Discrepancies between prespecified and published eligibility criteria make a proper
assessment of the applicability of trial results in clinical practice, research, and policy more
difficult
Trial protocols should be made publicly accessible to make the conduct and reporting of
clinical research more transparent
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